Voyager Therapeutics Inc (VYGR) was Initiated by Stifel to “Buy” and the brokerage firm has set the Price Target at $33. Stifel advised their investors in a research report released on Jul 15, 2016.
Many Wall Street Analysts have commented on Voyager Therapeutics Inc. Voyager Therapeutics Inc was Initiated by Wells Fargo to “Outperform” on May 20, 2016.
In a different news, on Jan 15, 2016, Steven M Paul (CEO) purchased 10,000 shares at $14.07 per share price.
Voyager Therapeutics Inc. is a clinical-stage gene therapy company. The Company focuses on developing life-changing treatments for patients suffering from severe diseases of the central nervous system (CNS). Its product engine has generated programs for five CNS indications including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis; Friedreich’s ataxia; Huntington’s disease and spinal muscular atrophy. The Company’s gene therapy approach uses adeno-associated virus (AAV) vectors which are modified non-replicating versions of AAV and which are ideal vectors for CNS gene therapy. It is also focused on gene replacement and gene knockdown approaches. Its products are VY-AADC01 program for advanced Parkinson’s disease VY-SOD101 for a monogenic form of Amyotrophic lateral sclerosis (ALS) VY-FXN01 for Friedreich’s ataxia VY-HTT01 for Huntington’s disease and VY-SMN101 for spinal muscular atrophy (SMA).